Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
Portfolio Pulse from
Neurocrine Biosciences, Inc. (NBIX) experienced a share price decline due to phase 2 results of NBI-568, but the drop seems excessive. The company is trading at low multiples despite strong growth from Ingrezza and the upcoming launch of crinecerfont in 2025.
November 08, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' stock price fell after phase 2 results for NBI-568, but the decline may be overdone. The company is undervalued given its growth potential with Ingrezza and the upcoming crinecerfont launch.
The decline in NBIX's stock price is attributed to the phase 2 results of NBI-568, but the company's strong growth from Ingrezza and the future launch of crinecerfont suggest that the stock is undervalued. This presents a potential buying opportunity as the market may correct this undervaluation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100